The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2018 | CAR T-cells in hematological malignancies
Stephen Robinson, MBBS, MRCP, MRCPath, PhD, of University Hospitals Bristol NHS Foundation Trust, Bristol, UK, speaks to us about one of the most exciting developments in hematological oncology: CAR T-cells. This therapy, which allows the patient’s own immune system to target and attack tumors has been shown to be particularly effective in patients with aggressive, refractory diffuse large B-cell lymphoma (DLBCL), and children with acute lymphoblastic leukemia (ALL). Dr Robinson notes that the field is still very much in infancy, and longer term follow up and clinical studies are essential to evaluate the efficacy of CAR T-cell therapy. This video was filmed at the British Society for Haematology (BSH) 2018 Annual Scientific Meeting, in Liverpool, UK.
